What's new? Log in Free sign up

KORU Medical Systems (KRMD)

Company Profile

Company profile

Ticker

KRMD

Exchange

Website

www.korumedical.com

CEO

Ms. Linda M. Tharby

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...

Former names

REPRO MED SYSTEMS INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

133044880

KRMD stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$5.17

Low target

$4.50

High target

$6.00

Latest filings (excl ownership)

View all

Results of Operations and Financial Condition

Quarterly report

13 Nov 24

Koru Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-digit Growth; Raises Full Year 2024 Guidance

Departure of Directors or Certain Officers

Koru Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter with 22% Revenue Growth; Raises Full Year 2024 Guidance

Quarterly report

7 Aug 24

Entry into a Material Definitive Agreement

Registration of securities for employees

Registration of securities for employees (post-effective amendment)

Changes in Registrant's Certifying Accountant

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

First Light Asset Management, LLC

Joseph M. Jr. Manko

Horton Capital Partners, LLC

Joseph M. Jr. Manko

EDWARD WHOLIHAN

ROBERT CASCELLA

R JOHN FLETCHER

Joseph M. Jr. Manko

Financial summary

Financial statements Chart KRMD financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	8.81 mm	8.81 mm	8.81 mm	8.81 mm	8.81 mm	8.81 mm
Cash burn (monthly)	550.56 k	163.82 k	567.77 k	587.85 k	307.98 k	13.54 k
Cash used (since last report)	2.91 mm	865.94 k	3.00 mm	3.11 mm	1.63 mm	71.59 k
Cash remaining	5.90 mm	7.94 mm	5.81 mm	5.70 mm	7.18 mm	8.73 mm
Runway (months of cash)	10.7	48.5	10.2	9.7	23.3	644.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

KRMD institutional ownership history Ownership history

55.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	56	66	-15.2%
Opened positions	6	24	-75.0%
Closed positions	16	16	–
Increased positions	12	11	+9.1%
Reduced positions	24	21	+14.3%

13F shares	Current	Prev Q	Change
Total value	34.90 bn	38.00 bn	-8.2%
Total shares	25.42 mm	25.14 mm	+1.1%
Total puts	3.80 k	300.00	+1166.7%
Total calls	3.00 k	0.00	NEW
Total put/call ratio	1.3	Infinity	NaN%

Largest owners	Shares	Value	Change
Horton Capital Partners	8.06 mm	$19.75 mm	0.0%
First Light Asset Management	5.60 mm	$15.29 bn	+11.1%
Topline Capital Management	4.59 mm	$12.06 mm	+67.4%
Vanguard	1.78 mm	$4.87 bn	0.0%
Meros Investment Management	805.38 k	$2.20 bn	+0.1%
Albion Financial	667.78 k	$1.82 bn	-5.3%
RBF Capital	521.32 k	$1.42 bn	-34.7%
Geode Capital Management	462.13 k	$1.26 bn	+6.5%
272 Capital	302.12 k	$824.77 mm	-2.0%
Millennium Management	271.52 k	$741.26 mm	-42.2%

Largest transactions	Shares	Bought/sold	Change
Topline Capital Management	4.59 mm	+1.85 mm	+67.4%
Archon Capital Management	188.90 k	-859.11 k	-82.0%
First Light Asset Management	5.60 mm	+560.54 k	+11.1%
GS The Goldman Sachs Group, Inc.	0.00	-404.93 k	EXIT
RBF Capital	521.32 k	-277.13 k	-34.7%
Millennium Management	271.52 k	-198.14 k	-42.2%
NTRS Northern Trust	71.21 k	-189.37 k	-72.7%
BLK BlackRock	0.00	-186.84 k	EXIT
BlackRock	186.02 k	+186.02 k	NEW
Alpine Global Management	0.00	-107.24 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KRMD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Feb 25	Manko Joseph M. Jr.	Common Stock	Other	Dispose J	Yes	No	0	16,187	0.00	5,871,677
21 Jan 25	Manko Joseph M. Jr.	Common Stock	Other	Acquire J	No	No	0	351,948	0.00	517,200
21 Jan 25	Manko Joseph M. Jr.	Common Stock	Other	Dispose J	Yes	No	0	1,000,000	0.00	0
21 Jan 25	Manko Joseph M. Jr.	Common Stock	Other	Acquire J	Yes	No	0	1,000,000	0.00	1,000,000
21 Jan 25	Manko Joseph M. Jr.	Common Stock	Other	Dispose J	Yes	No	0	1,000,000	0.00	5,887,864
3 Jan 25	Robert Cascella	Common Stock	Grant	Acquire A	No	No	3.81	3,937	15.00 k	74,556
3 Jan 25	Wholihan Edward	Common Stock	Grant	Acquire A	No	No	3.81	3,937	15.00 k	27,713
3 Jan 25	Shahriar Matin	Common Stock	Grant	Acquire A	No	No	3.81	3,937	15.00 k	77,545

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

This Informatica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Piper Sandler Downgrades KORU Medical Systems to Neutral, Maintains Price Target to $4.5

Piper Sandler analyst Jason Bednar downgrades KORU Medical Systems (NASDAQ:KRMD) from Overweight to Neutral and maintains the price target from $4.5 to $4.5.

KORU Medical Signs Agreement For Next-Gen Subcutaneous Infusion System With Global Pharmaceutical Company; Co Collaborates With SCHOTT Pharma

KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large

KORU Medical Announces Collaboration With A Global Pharmaceutical Manufacturer For Phase III Trial On Renal Disorder, Targeting 30K Patients With 300K Annual Infusions; Focusing On Drug Safety, Efficacy, And Performance For Kidney Transplant Complications

Analyst Expectations For KORU Medical Systems's Future

Press releases

From Benzinga Pro

KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large

KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System

KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large

KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.